Shanghai Henlius Biotech, Inc. Class H · HKEX:2696
Shanghai Henlius Biotech, Inc. Class H — FY2021 Earnings Presentation
45 slides from Shanghai Henlius Biotech, Inc. Class H's earnings presentation, March 2022
Slide 1: 2021 Annual Results Investor Presentation
Henlius 2696.HK 2021 Annual Results Investor Presentation March 2022 © 2022 Henlius.
Slide 2: Contents
01 Company Overview and Strategy 02 Organization Capability CONTENTS 03 Core Business System R&D Manufacturing Commercial Operation 04 2021 Financial Review & 2022 Outlook © 2022 Henlius.
Slide 3: Company Overview & Strategy
01 Company Overview & Strategy © 2022 Henlius.
Slide 4: Company Mission & Key Milestones
Company Mission & Key Milestones Mission: 2022H1 Songjiang First Plant Capacity of 24,000L Expected to be in Commercial Operation Affordable Innovation, Reliable Quality HLX10 (PD-1 mAb, serplulimab) MSI-H Solid Tumor Indication 2022Q2 Expected to be Approved HLX01 (rituximab, HANLIKANG) Innovative
Slide 5: H-evolution: From Biotech to Biopharma
H-evolution: From Biotech to Biopharma, Operational Enhancement Biotech Biopharma Partial function setup Full value chain Singular/few products Comprehensive portfolio H-evolution Mostly organic, In-licensing dependent supplemented with external Thin revenue, cash burning Sizable revenue, self finan
Slide 6: Strategy: Maximize Biosimilar Commercial Value, Accelerate Innovation
Strategy:Maximize Biosimilar Commercial Value, Accelerate Diversified Innovation with Full Speed Strategic Goals Commercialization:Biosimilar Commercialization:Serplulimab While maximizing biosimilar Accelerate capacity expansion, HLX02 Successful China market approval and commercial value, rely on
Slide 7: Organization Capability
02 Organization Capability © 2022 Henlius.
Slide 8: A Fully-Integrated Platform
A Fully-Integrated Platform Global R&D, RA, Clinical Development Commercial-scale Manufacturing Global Commercial Platform & Operation Platform Facilities • Continuing its momentum for a diversified innovation • Manufacturing facility scaling up: • Building top in-house commercial team in the indust
Slide 9: All-Round Improvement, Casting Henlius-Quality
All-Round Improvement, Casting Henlius-Quality Culture buildup Mid-level management team Henlius’ Quality- Strengthen and bring out full centric culture potential of mid-level management Process optimization Further improve system and process efficiency Leadership team Compliance Solidarity, stabili
Slide 10: Management Team: Solidarity, Stability, Innovation
Management Team: Solidarity, Stability, Innovation Jason Zhu Wei Huang James Guo Jean-Michel Gries Gino Li Kurt Yu President Chief Operation Officer SVP President of Hengenix Chief Financial Officer Chief Commercial Officer SVP Biotech VP VP Wenjie Zhang Chairman Executive Director and CEO • Joined
Slide 11: Company Size: the Number of Employees Rapidly Grew
Company Size: the Number of Employees Rapidly Grew Company Size and Composition* R&D 335 R&D/Clinical Manufacturing/Quality Commercial Administrative 2500 Clinical 304 2,234 Manufacturing 610 203 Quality 255 2000 1,873 Commercial 527 203 527 Administrative 203 1500 395 1,172 135 865 1000 53 693 527
Slide 12: 3.1 R&D
3.1 R&D © 2022 Henlius.
Slide 13: Leader in China Biopharmaceutical Industry
Leader in China Biopharmaceutical Industry 4 1 Products launched in Product launched in China the EU First China-developed adalimumab The only bevacizumab with First Chinese biosimilar First Chinese mAb biosimilar biosimilar manufactured in a China metastatic colorectal cancer HANLIKANG® (rituximab)
Slide 14: Diversified Product Pipelines: Innovative Biologics
Diversified Product Pipelines Based on Fully-Integrated R&D Platform- Innovative Biologics Products Targets Indications Pre-clinical IND Phase 1 Phase 2 Phase 3 NDA Launch Business Partners Priority Review Expe- mono PD-1 MSI-H solid tumours 2L+ cted Designation Soon Global multi-centre clinical stu
Slide 15: Serplulimab (anti-PD1 mAb): All Tumor Targeting
Serplulimab (anti-PD1 mAb): All Tumor Targeting, Differentiate Competition, Empoweringa Ecosystem and Global Layout Pave the Way for Globalization All Tumor Targeting Global China MSI-H solid tumors SC-NSCLC Lung SCLC cancer Head&Neck Esophageal International Multicenter Clinical Trial Reach Primary
Slide 16: Actively Propel Clinical Trials of HLX208
Actively Propel Clinical Trials of HLX208(BRAF V600E Inhibitor) and Accelerate to Get on the Market Strategy Core Clinical Trials Stage • “Fast to Market”Project • HLX208 is expected to be the second approved domestic BRAF • Non-Small Cell Lung Cancer(NSCLC) Ph 2 inhibitor in lung cancer • “Fast to
Slide 17: Diversified Product Pipelines: Biosimilar
Diversified Product Pipelines Based on Fully-Integrated R&D Platform-Biosimilar Business Products Targets Indications Pre-IND IND Phase 1 Phase 2 Phase 3 NDA Launch Partners non-Hodgkin lymphoma, HANLIKANG CD20 chronic lymphocytic leukemia (rituximab)(1) rheumatoid arthritis(5) HANQUYOU breast cance
Slide 18: Preclinical Projects Effectively Propel the IND Application
Preclinical Effectively Propel the IND Application for Preclinical Projects Emphasize on the preclinical projects, complete the IND application submissions domestically and internationally for preclinical products covering CD35, LAG-3 and CD73 targets. Submit the investigational new drug (IND) appli
Slide 19: Pre-Clinical: Dual Innovation Center, One-Team Culture
Pre-Clinical:Dual Innovation Center, One-Team Culture Emphasize one-team culture and foster close working relationship, open communication and effective collaboration Leverage global talent pool, innovative therapeutic expertise, key opinion leaders at both sites Synergize with Henlius strategic dev
Slide 20: Pre-Clinical: Build Proprietary AXC Technology Platform
Pre-Clinical:Build Proprietary AXC Technology Platform Antibody-Centric, Evolved Modality (AXC: Antibody X-molecule Conjugate) Based on antibody and novel conjugating technologies, expand different forms of antibody conjugates to address unmet clinical needs. Small molecule Cell (ACC) (ADC) Enzyme (
Slide 21: 3.2 Manufacturing
3.2 Manufacturing © 2022 Henlius.
Slide 22: Integrated Platform Advantage: Manufacturing Bases Construction
Integrated Platform Advantage: Manufacturing Bases Construction Will Further Increase Integrated Platform Advantage Continuous Improvement of Quality Management System In Compliance with Global GMP Standard • NMPA & EMA certified,FDA to be certified next • Continue to improve the quality management
Slide 23: Songjiang Site I: Commercial Scale Manufacturing Plant Completed
Songjiang Site I: Completed the Construction of Commercial Scale Manufacturing Plant and Pilot Scale Continuous Manufacturing Plant, and Commenced Manufacturing Successfully Commence Commercial Manufacturing • 2021.03 Completed the construction and qualification of DP filling line by Mid-2022 • 2021
Slide 24: Songjiang Site II: Accelerate Construction of Intelligent Factory
Songjiang Site II Accelerate the Construction of the Intelligent Factory Total Capacity 36,000L for Phase I Phase I 3rd Stage construction program 1st & 2nd Stage landed with a designed capacity of 60,000L • Completed the main structure and secondary structure of the two main • Designed 15KL mass st
Slide 25: 3.3 Commercial Operation
3.3 Commercial Operation © 2022 Henlius.
Slide 26: Upgrade Commercialization by Enhancing Core Capabilities
Upgrade Commercialization by Enhancing Core Capabilities Maximize commercial value of late-stage assets Access Sales • NRDL & PRDL • Professional • Tendering • Customer-oriented • Hospital listing • Efficient implementation Channel Marketing • Distribution network • Comprehensive and sustainable • D
Slide 27: Pursuing Strategic Collaborations to Establish Global Presence
For Global: Pursuing Strategic Collaborations to Establish Global Presence KG Bio FARMA DE COLOMBIA HLX10 (Serplulimab) HANLIKANG® (rituximab) Philippines, Indonesia, Malaysia, Singapore, Accord Colombia, Peru, Ecuador and Venezuela Thailand, Laos, Myanmar, Cambodia, Brunei HANQUYOU® (trastuzumab) a
Slide 28: HANQUYOU (trastuzumab): Established Commercialization System
HANQUYOU® (trastuzumab) : Established Commercialization System to Lead Rapid Business Growth Continue to Optimize Distribution Network Market Access Continues to Advance • Domestic market: 150mg: completed bidding and medical • Optimize distributors & DTP pharmacy, reduce multi-tier insurance procur
Slide 29: HANQUYOU: Not Leaving Any HER2+ Breast Cancer Patient Behind
HANQUYOU® (trastuzumab): “Not Leaving Any HER2+ Breast Cancer Patient Behind” Collaboration on Physician Education Collaboration on Market Access • Collaborate with medical societies, facilitate at • Collaborate with the government to promote the community level research of biosimilar medical insura
Slide 30: HANQUYOU: Excellent Sales Performance
HANQUYOU® (trastuzumab) : Excellent Sales Performance to Lead a Healthy and Sustainable Development Sales Performance Investment-Effectiveness Total accessed market reaches 60% * by Dec. 2021, market Enhance sales capability and investment efficiency to share in accessed market surpassed originator
Slide 31: HANQUYOU Outlook: Become Market Leader
HANQUYOU® (trastuzumab) Outlook : Become Market Leader by Seizing Opportunities to Increase Sales Volume Quickly • Accelerate bidding and medical insurance Redefine clinical procurement platform of 60mg specifications, practice standard of expected to complete all provinces and trastuzumab infusion
Slide 32: HANLIKANG (rituximab): Continue to Increase Volume
HANLIKANG® (rituximab) :Continue to Increase Volume and Become the Market Leader Market Access Sales Performance Ex-factory Sales 100mg: Ex-Factory Volume* (Unit: 10000 vials) • 28 provinces and municipalities had completed official platform/filed procurement, 30 provinces and 80.61 municipalities h
Slide 33: HANLIKANG: First Entrant and Market Segmentation Differentiation
HANLIKANG® (rituximab) : Take Advantage of First Entrant and Market Segmentation Differentiation • Enhance the brand awareness of HANLIKANG® among doctors and the public, and increase the patient share and the DOT by initiating the patient journey management project for lymphoma patients • Enhance t
Slide 34: HANLIKANG Outlook: Strengthen Brand Penetration
HANLIKANG® (rituximab) Outlook: Strengthen Brand Penetration and Consolidate Leading Market Position • Accelerate hospital listing by resources Improvement on hospital integration and formulation of hospital listing in Top 300+ hospitals listing plan that is unique strategy to with low market penetr
Slide 35: HANSIZHUANG (serplulimab): Preparation for Successful Launch
HANSIZHUANG® (serplulimab) : Adequate Preparation for Successful Launch HANSIZHUANG® (Serplulimab) Launch Readiness Channel Access Team • Pursue synergistic effect • Collaborate with academic • Establish 200+ dedicated with HLX02, establish institutions on bio-innovative commercial team, which has e
Slide 36: HANSIZHUANG: Expected Approval for MSI-H Solid Tumor
HANSIZHUANG® (serplulimab) : Expected to be Approved for MSI-H Solid Tumor Indication Soon Market Prospects • 310k+ patients newly diagnosed per year • Existed in multiple tumor types Clinical Efficacy Profile MSI-H Solid Tumor • Highest 12-month OS rate among PD-(L)1 inhibitors Expected to be appro
Slide 37: HANSIZHUANG: Tap Market Potential through Ecosystem
HANSIZHUANG® (serplulimab) : Tap Market Potential through Ecosystem Establishment Ecosystem Empowerment Physician Education Market Access Empower innovative academic Improve patient affordability through communication platforms through PAP initiated by charity foundations and collaboration with medi
Slide 38: HANSIZHUANG: Expected Approval for sqNSCLC in 2H 2022
HANSIZHUANG® (serplulimab) : Expected to be Approved for sqNSCLC Indication in the Second Half of 2022 Market Prospects • 800k+ patients of Lung Cancer newly diagnosed per year (170k+ in sqNSCLC,120k + in SCLC) • First anti-PD-1 mAb for first-line treatment of SCLC Lung Cancer Clinical Efficacy Prof
Slide 39: 2021 Financial Review & 2022 Outlook
04 2021 Financial Review & 2022 Outlook © 2022 Henlius.
Slide 40: 2021 Sales: Increased Rapidly Led by Core Products
2021 Sales: Increased Rapidly Lead by the Core Products Composition of Income (in RMB 100M) Ex-Factory Volume * (in 1000 Vials) HANLIKANG HANQUYOU HANDAYUAN BD & Other Income HANDAYUAN HANQUYOU HANLIKANG 18.00 160.00 222.78 Vials 16.82 138.41 140.00 16.00 1.88 120.00 0.22 14.00 100.00 87.80 Vials 72
Slide 41: 2021 R&D: Expenditure Grow with More on Innovative Drugs
2021 R&D: Expenditure Grow with More on Innovative Drugs R&D Expenditure (in RMB 100M) Ratio of Expensed R&D Expenditure Ratio of Bio-Innovative Expense 58% 20.00 60% 90% 81.75% 52% 75.48% 80% 15.00 50% 8.94 10.24 70% 64.54% 6.08 43% 10.00 60% 40% 38% 5.00 50% 7.99 8.17 7.40 42.15% 30% 40% - 2018 20
Slide 42: 2021 Loss Ratio & Expense Ratio: Largely Decreased
2021 Loss Ratio & Expense Ratio: Largely Decreased The Ratio of Loss to Total Revenue Narrowed Down The Ratio of Expense to Total Revenue Loss Rate 2020 2021 0% 160.00% 152.17% 2019 2020 2021 -100% 140.00% -58% -200% -169% 120.00% -300% 100.00% -400% 80.00% -500% 60.86% -600% 60.00% 41.47% -700% 40.
Slide 43: 2022 Outlook: Successful Evolution from Biotech to Biopharma
2022 Outlook Successful Evolution from Biotech to Biopharma ! © 2022 Henlius.
Slide 44: Disclaimer
声明 Disclaimer • 复宏汉霖、陈述人或提供人对本文件内容(文件内容亦有可能包括前瞻性陈述)均不做出明示或默示的保证、声明或陈述(包括但不限于:本内容针对为任意特定目的而关于内容 所具有的及时性、通用性、精确性的声明,或者关于使用本文件内容所获得信息无误可信的声明)。如因有关内容存在错误、遗漏或失准之处而引致的行为或结果,复宏汉霖、陈 述人或提供人对此不承担责任。 • 本文件及其中所包含内容的所有权利包括版权均由复宏汉霖独家所有,其中相关的“Henlius” 和“复宏汉霖”字样、图案及相关LOGO标识均为复宏汉霖合法所有的字号、商标 和标识。未经复宏汉霖书面同意,任何第三方不得以包括
Slide 45: © 2022 Henlius.
A | Henlius #22:3V% ARENA Sia Mio Reliable Quality Affordable Innovation
Shanghai Henlius Biotech — FY2021 Earnings Presentation on 6ix